Minerva Neurosciences | NERV - Ativo Circulante





Ativo Circulante Alterar Data
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Adma Biologics USD 466.51M 63.86M 2025-12
ALKERMES USD 1.36B 570.52M 2026-03
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
AstraZeneca USD 29.61B 890M 2026-03
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cipla INR 249.18B 16.3B 2025-09
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 148.02M 59.1M 2025-12
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 462.57M 102.11M 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Novavax USD 978.28M 3.69M 2025-12
Pfizer USD 42.82B 76M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sanofi EUR 30.16B 789M 2026-03
Takeda JPY 3.12T 195.82B 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12